These results demonstrated that the combination therapy of Acar and low-dose CsA could inhibit the development of IMQ-induced psoriasis-like dermatitis in mice and reduce the levels of Th1-related cytokines (TNF-α) and Th17-related cytokines (IL-17A, IL-22, and IL-23) in serum and skin compared with treatment with Acar alone or low-dose CsA alone. This evidence concerns the gene IL17A and psoriasis.